|
The role of zinc deficiency in the development of non-alcoholic fatty liver disease (NAFLD): a descriptive review
|
Bahareh Shateri amiri *1   , Haleh Chehrehgosha2 |
1- Assistant Professor of Internal Medicine, Department of Internal Medicine, School of Medicine, Hazrat-E Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran, tehran , shateri.bahareh@yahoo.com
2- Hazrat Rasool Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran., tehran |
|
|
Abstract: (399 Views) |
| Nonalcoholic fatty liver disease (NAFLD) represents a global health problem affecting approximately 30% of the population, ranging from simple steatosis to more severe conditions such as nonalcoholic steatohepatitis (NASH) and cirrhosis. Recent research highlights a worrisome link between zinc deficiency and NAFLD, as zinc plays an important role in metabolic processes, including glucose and lipid metabolism, insulin signaling, and antioxidant defense.This review synthesizes the existing literature on the mechanisms related to zinc deficiency in NAFLD, emphasizing its contribution to endoplasmic reticulum stress, inflammation, insulin resistance, and oxidative stress. Evidence suggests that zinc supplementation may improve liver metabolic and histological parameters in NAFLD patients.Clinical trials show that zinc supplementation can lead to a significant reduction in body mass index, waist circumference, and liver enzymes. However, although these findings are promising, they require further investigation to determine optimal doses and long-term effects. Overall, addressing zinc deficiency can be a critical aspect of NAFLD management alongside traditional lifestyle modification. |
|
| Keywords: Non-alcoholic fatty liver, zinc deficiency, metabolic syndrome |
|
|
Full-Text [PDF 618 kb]
(107 Downloads)
|
Type of Study: Letter to editor |
Subject:
Special
Received: 2024/08/31 | Accepted: 2024/09/20 | Published: 2024/09/20
|
|
|
|
|
|
|
| References |
1. Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Translational gastroenterology and hepatology. 2020;5(16):1-17. [ DOI:10.21037/tgh.2019.09.08] [ PMID] [ ] 2. Pickett-Blakely O, Young K, Carr RM. Micronutrients in nonalcoholic fatty liver disease pathogenesis. Cellular and Molecular Gastroenterology and Hepatology. 2018 Jan 1;6(4):451-62. [ DOI:10.1016/j.jcmgh.2018.07.004] [ PMID] [ ] 3. Sumaily KM. The roles and pathogenesis mechanisms of a number of micronutrients in the prevention and/or treatment of chronic hepatitis, COVID-19 and type-2 diabetes mellitus. Nutrients. 2022 Jun 24;14(13):2632. [ DOI:10.3390/nu14132632] [ PMID] [ ] 4. Barbara M, Mindikoglu AL. The role of zinc in the prevention and treatment of nonalcoholic fatty liver disease. Metabolism Open. 2021 1;11:100-105. [ DOI:10.1016/j.metop.2021.100105] [ PMID] [ ] 5. Himoto T, Masaki T. Associations between zinc deficiency and metabolic abnormalities in patients with chronic liver disease. Nutrients. 2018 14;10(1):88-98. [ DOI:10.3390/nu10010088] [ PMID] [ ] 6. Akdas S, Yazihan N. Serum zinc level and dietary zinc intake status in non-alcoholic fatty liver disease: A meta-analysis and systematic review. Hepatol Forum. 2020 21;1(2):59-67. [ DOI:10.14744/hf.2020.2020.0006] [ PMID] [ ] 7. Fujii H, Kawada N, Japan Study Group of Nafld (JSG-NAFLD). The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. International journal of molecular sciences. 2020 May 29;21(11):3863. [ DOI:10.3390/ijms21113863] [ PMID] [ ] 8. Marreiro DD, Cruz KJ, Morais JB, Beserra JB, Severo JS, De Oliveira AR. Zinc and oxidative stress: current mechanisms. Antioxidants. 2017;6(2):24. [ DOI:10.3390/antiox6020024] [ PMID] [ ] 9. Himoto T, Masaki T. Associations between zinc deficiency and metabolic abnormalities in patients with chronic liver disease. Nutrients. 2018 Jan 14;10(1):88. [ DOI:10.3390/nu10010088] [ PMID] [ ] 10. Li D, Zhao D, Du J, Dong S, Aldhamin Z, Yuan X, Li W, Du H, Zhao W, Cui L, Liu L. Heme oxygenase-1 alleviated non-alcoholic fatty liver disease via suppressing ROS-dependent endoplasmic reticulum stress. Life sciences. 2020 15;253:117678. [ DOI:10.1016/j.lfs.2020.117678] [ PMID] 11. Stehbens WE. Oxidative stress, toxic hepatitis, and antioxidants with particular emphasis on zinc. Experimental and molecular pathology. 2003 1;75(3):265-76. [ DOI:10.1016/S0014-4800(03)00097-2] [ PMID] 12. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The role of oxidative stress and antioxidants in liver diseases. International journal of molecular sciences. 2015 2;16(11):26087-124. [ DOI:10.3390/ijms161125942] [ PMID] [ ] 13. Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Molecular aspects of medicine. 2005 1;26(4-5):391-404. [ DOI:10.1016/j.mam.2005.07.002] [ PMID] 14. Fogacci F, Giovannini M, Di Micoli V, Grandi E, Borghi C, Cicero AF. Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Nutrients. 2024 28;16(15):2454. [ DOI:10.3390/nu16152454] [ PMID] [ ] 15. Smita RM, Shuvo AP, Raihan S, Jahan R, Simin FA, Rahman A, Biswas S, Salem L, Sagor MA. The role of mineral deficiencies in insulin resistance and obesity. Current diabetes reviews. 2022 1;18(7):19-39. [ DOI:10.2174/1573399818666211117104626] [ PMID] 16. Eghbali S, Askari SF, Avan R, Sahebkar A. Therapeutic effects of Punica granatum (pomegranate): an updated review of clinical trials. Journal of nutrition and metabolism. 2021;2021(1):5297162. [ DOI:10.1155/2021/5297162] [ PMID] [ ] 17. Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez‐Campoy JM, Collazo‐Clavell ML, Spitz AFR et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity. 2009;17(S1):S3-72. [ DOI:10.1038/oby.2009.28] [ PMID] 18. Behrouz V, Dastkhosh A, Sohrab G. Overview of dietary supplements on patients with type 2 diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020 1;14(4):325-34. [ DOI:10.1016/j.dsx.2020.03.019] [ PMID] 19. Rezaei SM, Mohammadi F, Eftekhari MH, Ejtehadi F, Ghaem H, Mohammadipoor N. The effects of zinc supplementation on the metabolic factors in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial. BMC nutrition. 2023 Nov 27;9(1):138. [ DOI:10.1186/s40795-023-00776-z] [ PMID] [ ] 20. Fathi M, Alavinejad P, Haidari Z, Amani R. The effect of zinc supplementation on steatosis severity and liver function enzymes in overweight/obese patients with mild to moderate non-alcoholic fatty liver following calorie-restricted diet: a double-blind, randomized placebo-controlled trial. Biological trace element research. 2020;197:394-404. [ DOI:10.1007/s12011-019-02015-8] [ PMID] 21. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The role of oxidative stress and antioxidants in liver diseases. International journal of molecular sciences. 2015 2;16(11):26087-124. [ DOI:10.3390/ijms161125942] [ PMID] [ ] 22. Perlemuter G, Davit‐Spraul A, Cosson C, Conti M, Bigorgne A, Paradis V, Corre MP, Prat L, Kuoch V, Basdevant A, Pelletier G. Increase in liver antioxidant enzyme activities in non‐alcoholic fatty liver disease. Liver international. 2005;25(5):946-53. [ DOI:10.1111/j.1478-3231.2005.01126.x] [ PMID] 23. Dey A, Lakshmanan J. The role of antioxidants and other agents in alleviating hyperglycemia mediated oxidative stress and injury in liver. Food & function. 2013;4(8):1148-84. [ DOI:10.1039/c3fo30317a] [ PMID] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
|
